MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, reported today that the U.S. Food and Drug Administration approved its Pre-Market Approval (PMA) Supplement for the CELLPAKER® plasma collection system. The new approval permits Orthovita to sell CELLPAKER product that is manufactured at its subcontractor’s facility.
